| 2019-12-31 | Linvatec Corporation | $145 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | | 2019 |
| 2019-12-05 | Alnylam Pharmaceuticals Inc. | $2,421 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | The Study of an Investigational Drug, Patisiran ALN-TTR02, for the Treatment of Transthyretin TTR-Mediated Amyloidosis i | 2019 |
| 2019-11-26 | Sysmex America, Inc. | $409 | Travel and Lodging | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-26 | Sysmex America, Inc. | $404 | Travel and Lodging | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-26 | Sysmex America, Inc. | $207 | Travel and Lodging | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-26 | Sysmex America, Inc. | $202 | Travel and Lodging | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-26 | Sysmex America, Inc. | $19 | Food and Beverage | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-26 | Sysmex America, Inc. | $19 | Food and Beverage | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-25 | Sysmex America, Inc. | $37 | Food and Beverage | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-25 | Sysmex America, Inc. | $37 | Food and Beverage | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-25 | Sysmex America, Inc. | $37 | Food and Beverage | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-25 | Sysmex America, Inc. | $37 | Food and Beverage | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-25 | Sysmex America, Inc. | $37 | Food and Beverage | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-25 | Sysmex America, Inc. | $37 | Food and Beverage | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-11-23 | Novartis Pharmaceuticals Corporation | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | | 2019 |
| 2019-11-14 | Chiesi USA, Inc. | $1,200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KENGREAL Drug, CARDIOVASCULAR | | 2019 |
| 2019-11-13 | Abbott Laboratories | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cardiovascular- Research only Device, Cardiac Arrhythmias and Heart Failure | | 2019 |
| 2019-11-06 | AstraZeneca Pharmaceuticals LP | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | | 2019 |
| 2019-10-28 | PFIZER INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | | 2019 |
| 2019-10-28 | Sysmex America, Inc. | $613 | Travel and Lodging | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-10-28 | Sysmex America, Inc. | $416 | Travel and Lodging | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-10-28 | Sysmex America, Inc. | $416 | Travel and Lodging | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-10-28 | Sysmex America, Inc. | $30 | Travel and Lodging | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-10-28 | Sysmex America, Inc. | $6 | Travel and Lodging | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-10-28 | Sysmex America, Inc. | $6 | Travel and Lodging | Cash or cash equivalent | XN Series Device, Hematology | | 2019 |
| 2019-10-25 | Akcea Therapeutics, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TEGSEDI Drug, NEUROLOGY | | 2019 |
| 2019-10-22 | Medtronic Vascular, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Resolute Device, Stents | | 2019 |
| 2019-10-09 | Celgene Corporation | $1,500 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Regist | 2019 |
| 2019-10-03 | Surgical Specialties Corporation (us), Inc. (dba Corza Medical) | $12 | Food and Beverage | Cash or cash equivalent | Surgical wound closure product Medical Supply, Surgical wound closure product | | 2019 |
| 2019-09-20 | Alnylam Pharmaceuticals Inc. | $1,452 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | The Study of an Investigational Drug, Patisiran ALN-TTR02, for the Treatment of Transthyretin TTR-Mediated Amyloidosis i | 2019 |
| 2019-08-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $175 | Research payment | In-kind items and services | | COPD pragmatic randomised clinical trial | 2019 |
| 2019-07-23 | Akcea Therapeutics, Inc. | $8,420 | Research payment | Cash or cash equivalent | | ISIS 678354-CS2 | 2019 |
| 2019-06-14 | Alnylam Pharmaceuticals Inc. | $2,421 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | The Study of an Investigational Drug, Patisiran ALN-TTR02, for the Treatment of Transthyretin TTR-Mediated Amyloidosis i | 2019 |
| 2019-06-10 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 |
| 2019-06-10 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 |
| 2019-05-08 | Incyte Corporation | $35 | Research payment | Cash or cash equivalent | | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 |
| 2019-04-29 | Incyte Corporation | $1,890 | Research payment | Cash or cash equivalent | | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 |
| 2019-04-03 | Abbott Laboratories | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cardiovascular- Research only Device, Cardiac Arrhythmias and Heart Failure | | 2019 |
| 2019-03-04 | Alnylam Pharmaceuticals Inc. | $968 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | The Study of an Investigational Drug, Patisiran ALN-TTR02, for the Treatment of Transthyretin TTR-Mediated Amyloidosis i | 2019 |
| 2019-02-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,700 | Research payment | Cash or cash equivalent | | COPD pragmatic randomised clinical trial | 2019 |
| 2019-02-05 | Incyte Corporation | $1,440 | Research payment | Cash or cash equivalent | | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 |
| 2019-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,936 | Research payment | Cash or cash equivalent | PRADAXA Drug, CARDIOVASCULAR | GLORIA AF Registry Phase II III Core | 2019 |
| 2019-01-28 | Medline Industries LP | $2,500 | Charitable Contribution | Cash or cash equivalent | | | 2019 |
| 2019-01-18 | Celgene Corporation | $3,250 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Celgene - Connect MDSAML | 2019 |
| 2019-01-16 | Relievant Medsystems, Inc. | $16,677 | Research payment | Cash or cash equivalent | Intracept Device, Pain | INTRACEPT | 2019 |
| 2019-01-16 | Relievant Medsystems, Inc. | $5,169 | Research payment | Cash or cash equivalent | Intracept Device, Pain | INTRACEPT | 2019 |
Comments